
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas Inc is focused on developing therapies that target and degrade disease-causing proteins, leveraging its proprietary PROTAC technology, which has shown a significant safety advantage in comparative trials, as indicated by an observed 7% increase in AST among patients treated with ASP3082. The company's candidate ARV-806 demonstrated superior potency in preclinical models, reducing KRAS G12D protein levels over 40 times more effectively than existing clinical degraders, indicating a meaningful pharmacologic advantage that may enhance both efficacy and safety in targeted treatments for KRAS G12D mutant tumors. Furthermore, the promising results from ARV-806's synergistic effects with PD-1 blockade suggest that Arvinas's innovative approaches could lead to improved immunotherapy outcomes, enhancing the company's potential for successful commercialization and patient impact.
Bears say
The analysis indicates a negative outlook for Arvinas Inc, primarily due to concerns regarding revenue expectations and capital access. The projected peak revenue for vepdeg has been significantly reduced from $641.2 million to $296.9 million, reflecting less favorable market conditions and anticipated difficulty in market penetration. Additionally, the company faces potential challenges stemming from a declining response rate for its therapies, which, coupled with limitations in capital access, may hinder critical operations and delay the path to profitability.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares